Outlook Therapeutics shares plummeted 61.5% in pre-market trading after the US Food and Drug Administration declined to approve a drug to treat eye diseases.

Zhitongcaijing · 4d ago
Outlook Therapeutics shares plummeted 61.5% in pre-market trading after the US Food and Drug Administration declined to approve a drug to treat eye diseases.